Subject(s)
Antipsychotic Agents , Bipolar Disorder , Narcotic Antagonists , Schizophrenia , Schizophrenic Psychology , Humans , Antipsychotic Agents/adverse effects , Antipsychotic Agents/therapeutic use , Bipolar Disorder/diagnosis , Bipolar Disorder/drug therapy , Bipolar Disorder/psychology , Drug Interactions , Narcotic Antagonists/adverse effects , Narcotic Antagonists/therapeutic use , Receptors, Opioid, mu/antagonists & inhibitors , Schizophrenia/diagnosis , Schizophrenia/drug therapy , Treatment Outcome , Weight Gain/drug effectsSubject(s)
Antipsychotic Agents/therapeutic use , Schizophrenia/drug therapy , Antipsychotic Agents/administration & dosage , Antipsychotic Agents/adverse effects , Drug Administration Routes , Drug Administration Schedule , Drug Interactions , Half-Life , Humans , Metabolic Clearance Rate , Randomized Controlled Trials as TopicSubject(s)
Antiemetics/administration & dosage , Antineoplastic Agents/adverse effects , Aprepitant/administration & dosage , Nausea/drug therapy , Neurokinin-1 Receptor Antagonists/administration & dosage , Vomiting/drug therapy , Antiemetics/adverse effects , Aprepitant/adverse effects , Drug Interactions , Humans , Infusions, Intravenous , Nausea/chemically induced , Nausea/diagnosis , Neurokinin-1 Receptor Antagonists/adverse effects , Treatment Outcome , Vomiting/chemically induced , Vomiting/diagnosisABSTRACT
We investigated the share of branded and generic antipsychotics before and after the publication of the CATIE results in September, 2005. According to our data, the publication of the CATIE results has had very little impact on new patient starts. To determine the impact of CATIE on use of olanzapine (Zyprexa((R))) subsequent to first line therapy, we also examined product share for switch/add patients. We found that since the publication of the CATIE results, the use of olanzapine has stabilized, following a decline subsequent to first line therapy, and may potentially be growing very slowly. An expert commentary is provided on the data.
ABSTRACT
OBJECTIVE: This open-label, multi-center, non-randomized study evaluated the efficacy, safety and tolerability of olanzapine in the treatment of schizophrenia or schizophreniform disorder among Filipino patients. METHOD: Filipino outpatients with a DSM-IV diagnosis of either schizophrenia or schizophreniform disorder (N = 382) were enrolled in this study. They were treated with an initial dose of 10 mg/day of olanzapine with eventual titration to 5 to 20 mg/day as clinically indicated and were observed for 8 weeks. Efficacy was assessed with the Brief Psychiatric Rating Scale (BPRS) and Clinical Global Impression - Severity of Illness Scale (CGI-S). Safety was assessed by collecting adverse event reports and checking vital signs. RESULTS: Statistically significant reductions from baseline to endpoint in both the mean BPRS Total score (from 36.77 +/- 12.12 to 11.43 +/10.39, p0.001) and mean CGI-S score (from 4.64 +/- 0.79 to 2.61 +/- 1.06, p0.001) were seen. The proportion of patients showing 20 percent improvement based on the BPRS Total score was 93.4 percent. Only 51 (13.7 percent) patients reported at least one treatment-emergent adverse event. The most commonly reported were somnolence (3.2 percent), weight loss (2.2 percent), tachycardia (1.3 percent), and headache (1.1 percent). CONCLUSION: The study clearly demonstrates the efficacy, safety and tolerability of olanzapine in the treatment of schizophrenia and schizophreniform disorder among Filipino patients.
